Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
Quick Read RVMD has surged 492% over one year on daraxonrasib’s landmark pancreatic cancer data showing 13.2 versus…
Global drug makers face pricing pressure as China targets affordable healthcare
Global pharmaceutical companies posted mixed earnings in China last year, with some firms warning that 2026 will be…